Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: A subgroup analysis of the aspreva lupus management study
作者单位:Clinical Department, Vifor Pharmaceuticals, VIC, Canada[1]Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, United Kingdom[2]Department of Medicine (Nephrology), McMaster University, Hamilton, Canada, Department of Clinical[3]